Anti‐mitotic agent SB‐216 overcomes taxane resistance in castration‐resistant prostate cancer and exhibits anti‐tumour efficacy in pancreatic cancer
Our findings suggest that SB-216 is a promising candidate as a new generation of anti-mitotic agents for advanced cancer, and further exploration in combination with other agents is warranted.
Authors
- Shanshan Deng (ORCID: https://orcid.org/0000-0003-4646-5885)
- Duane D. Miller (ORCID: https://orcid.org/0000-0002-6093-0985)
- Bernd Meibohm (ORCID: https://orcid.org/0000-0003-3923-3648)
- Chun Cai (ORCID: https://orcid.org/0009-0003-3827-6221)
- Satyanarayana Pochampally (ORCID: https://orcid.org/0000-0001-7617-9906)
- Rui Wang (ORCID: https://orcid.org/0000-0001-9348-1058)
- Evan S. Glazer (ORCID: https://orcid.org/0000-0002-5796-0542)
- Wěi Li (ORCID: https://orcid.org/0000-0002-9522-4474)
- Yang Xie (ORCID: https://orcid.org/0000-0003-0656-5152)
- David P. Hamilton (ORCID: https://orcid.org/0009-0002-9874-945X)
Institutions
- University of Tennessee Health Science Center (US)
- West Cancer Center (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1111/bph.70294
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Oxnard Foundation
- National Institutes of Health
- National Cancer Institute